Point72 Asset Management’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.8M Buy
1,361,391
+460,895
+51% +$5.76M 0.02% 987
2025
Q4
$11.6M Buy
900,496
+783,896
+672% +$10.1M 0.01% 1261
2025
Q3
$1.51M Sell
116,600
-353,400
-75% -$4.72M ﹤0.01% 1559
2025
Q2
$8.37M Buy
+470,000
New +$8.19M 0.02% 802
2024
Q2
Sell
-32,600
Closed -$510K 2282
2024
Q1
$510K Sell
32,600
-335,800
-91% -$4.94M ﹤0.01% 1645
2023
Q4
$5.5M Buy
368,400
+356,856
+3,091% +$4.78M 0.01% 880
2023
Q3
$186K Sell
11,544
-13,289
-54% -$383K ﹤0.01% 1784
2023
Q2
$1.03M Buy
+24,833
New +$1.54M ﹤0.01% 1137
2019
Q3
Sell
-8,126
Closed -$514K 1366
2019
Q2
$514K Sell
8,126
-437
-5% -$22.1K ﹤0.01% 833
2019
Q1
$412K Buy
+8,563
New +$412K ﹤0.01% 886

Other funds holding NVCR

Point72 Asset Management's NVCR Position: Q1 2026 in Review

Point72 Asset Management increased its NovoCure (NVCR) stake by 51% in Q1 2026, buying an estimated $5.76M and bringing the position to 1,361,391 shares worth $14.8M. The position accounts for 0.02% of the portfolio, ranked #987.

Point72 Asset Management first reported a position in NVCR in Q1 2019 and has held it in 10 quarters since. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Point72 Asset Management held 1,361,391 shares of NovoCure worth $14.8M as of Q1 2026.
  • Point72 Asset Management bought 460,895 NovoCure shares in Q1 2026, an estimated $5.76M.
  • NovoCure made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #987 holding.
  • Point72 Asset Management first reported a position in NovoCure in Q1 2019 and has held it in 10 quarters since.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.